Researchers Correct Cancer Study After Miscalculation in Key Metabolic Process

Researchers at the University of Michigan School of Medicine have made a correction to a previously published study on cancer metabolism and tumor immunology. The correction, published in the journal Nature, involves a mistake in a figure preparation that was discovered in Extended Data Fig. 1j. The figure, which was mistakenly a duplicate image of condition A375 sup, has been updated in the HTML and PDF versions of the article. According to the correction, the mistake was due to a figure preparation error. The corrected figure now accurately represents the flow cytometry dot plot for condition SupSer. The correction was made to ensure the accuracy and integrity of the research findings. The original study, published on September 2, 2020, explored the role of the SLC43A2 gene in cancer metabolism and its impact on T cell methionine metabolism and histone methylation. The research team, led by authors Yingjie Bian and Wei Li, discovered that the SLC43A2 gene plays a crucial role in regulating T cell metabolism and histone methylation, which are essential for immune responses against cancer. "We are committed to the accuracy and integrity of our research findings," said Dr. Weiping Zou, a co-author of the study and director of the Center of Excellence for Cancer Immunology and Immunotherapy at the University of Michigan Rogel Cancer Center. "We appreciate the opportunity to correct this mistake and ensure that our research contributes to the advancement of cancer treatment and immunology." The correction does not affect the overall conclusions of the original study, which highlighted the importance of SLC43A2 in cancer metabolism and its potential as a therapeutic target. The research has significant implications for the development of new cancer treatments and immunotherapies. The University of Michigan School of Medicine is a leading institution in cancer research and treatment, and the correction is a testament to the institution's commitment to accuracy and integrity in research. The study's findings have the potential to improve our understanding of cancer metabolism and immune responses, leading to the development of more effective cancer treatments. The corrected study is now available online in the journal Nature, and the research team continues to explore the role of SLC43A2 in cancer metabolism and its potential as a therapeutic target.